Study highlights EU’s fragmented access to new medicine [Advocacy Lab Content]

Access to novel medicines continues to vary widely across EU member states. Though health remains mostly a national competence, a new Euractiv cross-country report shows patients in each country face unequal challenges when accessing new therapies.